TCGA-CN-6988-01A-11R-1915-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UNFOLDED_PROTEIN_RESPONSE+0.110
- MYC_TARGETS_V2+0.100
- MITOTIC_SPINDLE+0.090
- G2M_CHECKPOINT+0.050
- PI3K_AKT_MTOR_SIGNALING+0.030
- ADIPOGENESIS+0.000
- MTORC1_SIGNALING+0.000
- PEROXISOME-0.010
- PROTEIN_SECRETION-0.010
- ESTROGEN_RESPONSE_EARLY-0.030
Top 10 suppressed
- ANGIOGENESIS-0.570
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.570
- ALLOGRAFT_REJECTION-0.520
- INTERFERON_ALPHA_RESPONSE-0.520
- INTERFERON_GAMMA_RESPONSE-0.510
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.420
- INFLAMMATORY_RESPONSE-0.410
- IL6_JAK_STAT3_SIGNALING-0.400
- KRAS_SIGNALING_UP-0.400
- IL2_STAT5_SIGNALING-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-DK-AA76-01A-11R-A39I-07 | — | — | 0.913 |
| 2 | SRR1385036 | GTEX | — | 0.908 |
| 3 | TCGA-G2-AA3F-01A-12R-A42T-07 | — | — | 0.907 |
| 4 | a50c02ec-6ba9-4678-990d-6c74a8e9b7b5 | — | — | 0.901 |
| 5 | TCGA-G2-A3VY-01A-11R-A22U-07 | — | — | 0.901 |
| 6 | TCGA-GV-A3JW-01A-11R-A20F-07 | — | — | 0.897 |
| 7 | TCGA-LQ-A4E4-01A-11R-A266-07 | — | B | 0.892 |
| 8 | TCGA-AR-A0TR-01A-11R-A084-07 | — | B | 0.890 |
| 9 | TCGA-ZF-A9RL-01A-11R-A38B-07 | — | — | 0.888 |
| 10 | SRR1322163 | GTEX | — | 0.887 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 5 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UNFOLDED_PROTEIN_RESPONSE | 0.110 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.100 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.090 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.050 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.030 | Inavolisib | — uncovered |